Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods
Respiratory syncytial virus (RSV) is a massive medical burden on a global scale. Infants, children and the elderly represent the vulnerable populations. Currently there is no approved vaccine to protect against the disease. Vaccine development has been hindered by several factors including vaccine e...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2017.1363134 |
| _version_ | 1797677537585790976 |
|---|---|
| author | Trevor R. F. Smith Katherine Schultheis Kate E. Broderick |
| author_facet | Trevor R. F. Smith Katherine Schultheis Kate E. Broderick |
| author_sort | Trevor R. F. Smith |
| collection | DOAJ |
| description | Respiratory syncytial virus (RSV) is a massive medical burden on a global scale. Infants, children and the elderly represent the vulnerable populations. Currently there is no approved vaccine to protect against the disease. Vaccine development has been hindered by several factors including vaccine enhanced disease (VED) associated with formalin-inactivated RSV vaccines, inability of target populations to raise protective immune responses after vaccination or natural viral infection, and a lack of consensus concerning the most appropriate virus-associated target antigen. However, with recent advances in the molecular understanding of the virus, and design of highly characterized vaccines with enhanced immunogenicity there is new belief a RSV vaccine is possible. One promising approach is nucleic acid-based vaccinology. Both DNA and mRNA RSV vaccines are showing promising results in clinically relevant animal models, supporting their transition into humans. Here we will discuss this strategy to target RSV, and the ongoing studies to advance the nucleic acid vaccine platform as a viable option to protect vulnerable populations from this important disease. |
| first_indexed | 2024-03-11T22:46:37Z |
| format | Article |
| id | doaj.art-42c9b49eed1145b78469ac5cf9dc7153 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:46:37Z |
| publishDate | 2017-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-42c9b49eed1145b78469ac5cf9dc71532023-09-22T08:17:52ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2017-11-0113112626262910.1080/21645515.2017.13631341363134Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goodsTrevor R. F. Smith0Katherine Schultheis1Kate E. Broderick2Inovio Pharmaceuticals, Inc.Inovio Pharmaceuticals, Inc.Inovio Pharmaceuticals, Inc.Respiratory syncytial virus (RSV) is a massive medical burden on a global scale. Infants, children and the elderly represent the vulnerable populations. Currently there is no approved vaccine to protect against the disease. Vaccine development has been hindered by several factors including vaccine enhanced disease (VED) associated with formalin-inactivated RSV vaccines, inability of target populations to raise protective immune responses after vaccination or natural viral infection, and a lack of consensus concerning the most appropriate virus-associated target antigen. However, with recent advances in the molecular understanding of the virus, and design of highly characterized vaccines with enhanced immunogenicity there is new belief a RSV vaccine is possible. One promising approach is nucleic acid-based vaccinology. Both DNA and mRNA RSV vaccines are showing promising results in clinically relevant animal models, supporting their transition into humans. Here we will discuss this strategy to target RSV, and the ongoing studies to advance the nucleic acid vaccine platform as a viable option to protect vulnerable populations from this important disease.http://dx.doi.org/10.1080/21645515.2017.1363134respiratory syncytial virusvaccine deliverydna/rna vaccine |
| spellingShingle | Trevor R. F. Smith Katherine Schultheis Kate E. Broderick Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods Human Vaccines & Immunotherapeutics respiratory syncytial virus vaccine delivery dna/rna vaccine |
| title | Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods |
| title_full | Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods |
| title_fullStr | Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods |
| title_full_unstemmed | Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods |
| title_short | Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods |
| title_sort | nucleic acid based vaccines targeting respiratory syncytial virus delivering the goods |
| topic | respiratory syncytial virus vaccine delivery dna/rna vaccine |
| url | http://dx.doi.org/10.1080/21645515.2017.1363134 |
| work_keys_str_mv | AT trevorrfsmith nucleicacidbasedvaccinestargetingrespiratorysyncytialvirusdeliveringthegoods AT katherineschultheis nucleicacidbasedvaccinestargetingrespiratorysyncytialvirusdeliveringthegoods AT kateebroderick nucleicacidbasedvaccinestargetingrespiratorysyncytialvirusdeliveringthegoods |